Skip to main content
. 2021 Dec 9;43(1):28–39. doi: 10.1093/carcin/bgab118

Figure 4.

Figure 4.

BRB-E enhances HSD11B2 expression and decreases tumorigenic properties in HNSCC cells. (A) RT–PCR analysis of HSD11B2 in control or BRB-treated samples. (B) Representative western blot image depicting the HSD11B2 protein levels in CAL27 cells treated with BRB-E—20 and 200 µg/ml, along with quantification of HSD11B2 band intensity. (C) Cortisol levels in conditioned media of control or BRB-E-treated CAL27 cells for 24 h as assessed by ELISA. Gene expression analysis of (D) PCNA, (E) BCL2 and (F) CDK1A in CAL27 cells treated with different concentrations of BRB-E for 24 h. All data are presented as mean ± SE from two independent experiments (N = 6 samples per group). *P < 0.05, **P < 0.01 and ****P < 0.0001 for comparisons between control, 20 and 200 µg/ml of BRB-E.